Bristol Myers says KRAS drug succeeds in key trial
BioPharma Drive: Drug Pricing
MARCH 29, 2024
Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.
Let's personalize your content